Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
| ▸ | PIEZO1 | Q92508 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474869 | 0.88 | KMT2A (0.40) | DGAT1IDO1EGFRTDO2NPC1 | |
| SCHEMBL5474880 | 0.88 | DGAT1 (0.40) | DGAT1IDO1EGFRTDO2TP53 | |
| SCHEMBL3883718 | 0.76 | MAP2K1 (0.42) | IDO1 | |
| SCHEMBL5477797 | 0.76 | IDO1 (0.40) | IDO1TDO2NPC1RAB9AGAA | |
| SCHEMBL5485313 | 0.76 | TDO2 (0.38) | IDO1TDO2NPC1RAB9AATAD2 | |
| SCHEMBL2024339 | 0.69 | GAA (0.36) | EGFRTP53GAAKDM4CMAPT | |
| SCHEMBL2018545 | 0.68 | KDR (0.38) | EGFRGAA | |
| SCHEMBL2029046 | 0.68 | ALOX12 (0.42) | EGFRTDO2NPC1RAB9AKDM4C | |
| SCHEMBL14392323 | 0.67 | — | — | |
| SCHEMBL15423725 | 0.66 | ALOX15 (0.46) | NPC1RAB9AL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | NRAS, MAP3K5, MAP3K1 | DGAT1 2633/4885IDO1 786/4885EGFR 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.